• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[超微结构形态学在人恶性黑色素瘤溶瘤产物制备中的价值]

[Value of ultrastructural morphology in the preparation of oncolysates of human malignant melanoma].

作者信息

Noël P, Faucon M, Leftheriotis E, Fontanière B, Bailly C, Carcagne C, Groleas M, Rezvoy M

出版信息

Ann Anat Pathol (Paris). 1979;24(2):125-35.

PMID:525843
Abstract

The culture of human cutaneous malignant melanomas is an important stage in the preparation of oncolysates for therapeutic purposes. The authors recall the definition of oncolysate: lysis of the malignant melanocyte by vaccinia virus liberates masked antigens which when reinjected into the patient accelerate or restimulate the production of antibodies. Culture is used to increase the number of malignant melanocytes, i. e. antigenic material, which is an essential precaution in tumours of small size. Production of oncolysate requires the exclusive use of the malignant melanocyte, i. e. the importance of morphological identification during the "in vitro" phase. The optical criteria defined by Fedoroff are inadequate and a source of error. Ultrastructural studies render this identification more valid, insofar as the normal and pathological markers which are the melanosomes are better known. Ultrastructural studies may be used to differentiate the malignant melanocyte from the ordinary macrophage in media which are black, and light cultures to distinguish fibroblastic growth, with no antigenic value, from the malignant melanocyte without pigment (achromic), recognisable by its premelanosome.

摘要

人皮肤恶性黑色素瘤的培养是制备用于治疗目的的肿瘤溶解产物的重要阶段。作者回顾了肿瘤溶解产物的定义:痘苗病毒对恶性黑素细胞的裂解会释放出隐蔽抗原,当将这些抗原重新注入患者体内时,会加速或重新刺激抗体的产生。培养用于增加恶性黑素细胞的数量,即抗原物质的数量,这对于小尺寸肿瘤来说是一项必不可少的预防措施。肿瘤溶解产物的生产需要专门使用恶性黑素细胞,即在“体外”阶段进行形态学鉴定的重要性。费多罗夫定义的光学标准并不充分,且是误差来源。超微结构研究使这种鉴定更具有效性,因为作为黑素小体的正常和病理标记物更为人所知。超微结构研究可用于在黑色培养基中区分恶性黑素细胞与普通巨噬细胞,以及在浅色培养物中区分无抗原价值的成纤维细胞生长与无色素(无色)的恶性黑素细胞,后者可通过其前黑素小体识别。

相似文献

1
[Value of ultrastructural morphology in the preparation of oncolysates of human malignant melanoma].[超微结构形态学在人恶性黑色素瘤溶瘤产物制备中的价值]
Ann Anat Pathol (Paris). 1979;24(2):125-35.
2
[Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].[黑色素瘤患者使用疫苗病毒的黑色素瘤溶瘤产物进行免疫治疗的反应]
Bull Cancer. 1990;77(9):881-91.
3
Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.在用痘苗病毒黑色素瘤溶瘤产物免疫的患者中诱导针对分子量31,000黑色素瘤抗原的IgG抗体。
Cancer Res. 1994 May 1;54(9):2433-9.
4
Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.人类黑素细胞痣和黑色素瘤肿瘤进展阶段的抗原特征
Cancer Res. 1989 Sep 15;49(18):5091-6.
5
[The treatment of advanced malignant melanoma with vaccina oncolysates (author's transl)].用牛痘溶瘤产物治疗晚期恶性黑色素瘤(作者译)
Nouv Presse Med. 1979 May 26;8(23):1919-21.
6
Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.
Cancer. 1977 Aug;40(2):672-9. doi: 10.1002/1097-0142(197708)40:2<672::aid-cncr2820400213>3.0.co;2-y.
7
Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.由小鼠单克隆抗体定义的黑色素瘤和黑色素细胞的表面抗原:培养细胞和组织中抗原表达的特异性分析与比较
Cancer Res. 1985 Sep;45(9):4401-11.
8
Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture.黑色素瘤相关抗原在体外快速分裂的人黑素细胞中的表达。
Cancer Res. 1987 Jun 15;47(12):3057-61.
9
Ultrastructural comparison between cultured and tumor cells of human malignant melanoma.
Cancer Res. 1977 Nov;37(11):3957-63.
10
Biology of tumor progression in human melanocytes.人类黑素细胞肿瘤进展的生物学
Lab Invest. 1987 May;56(5):461-74.